Occupational exposure to beryllium in primary aluminium production.

Alumina used in the production of primary aluminium contains Be which partly vaporises from the cryolite bath into the workroom atmosphere. Since Be may be toxic at lower exposure levels than previously thought, the personal exposure to Be among workers in 7 Norwegian primary smelters has been assessed. In total, 480 personal Respicon® virtual impactor full shift air samples have been collected during 2 sampling campaigns and analysed for water soluble Be, Al and Na using inductively coupled plasma optical emission spectrometry. In addition, water soluble F(-) has been measured by ion chromatography. The Be air concentrations in the inhalable, thoracic and respirable aerosol fractions have been calculated. The Be concentrations in the inhalable aerosol fraction vary between the different smelters. The highest GM concentration of Be in the inhalable fraction (122 ng m(-3), n = 30) was measured in the prebake pot room of a smelter using predominantly Jamaican alumina where also the highest individual air concentration of 270 ng m(-3) of Be was identified. The relative distribution of Be in the different aerosol fractions was fairly constant with the mean Be amount for the two sampling campaigns between 44-49% in the thoracic fraction expressed as % of the inhalable amount. Linear regression analysis shows a high correlation between water soluble Be, Al, F and Na describing an average measured chemical bulk composition of the water soluble thoracic fraction as Na(5.7)Al(3.1)F(18). Be is likely to be present as traces in this particulate matter by replacing Al atoms in the condensed fluorides and/or as a major element in a nanoparticle sized fluoride. Thus, the major amount of Be present in the work room atmosphere of Al smelter pot rooms will predominantly be present in combination with substantial amounts of water soluble Al, F and Na.

The fate of Gd and chelate following intravenous injection of gadodiamide in rats.

OBJECTIVE: The biodistribution of gadolinium (Gd) and chelate was studied in rats injected intravenously with a commercially available gadodiamide magnetic resonance contrast agent spiked with trace amounts of (14)C-labelled GdDTPA-BMA. METHODS: Biodistribution of the (14)C-labelled ligand in whole animals was visualised using quantitative whole-body autoradiography, and quantified in individual tissue samples by analysing for radioactivity using beta-counting. Biodistribution of Gd was measured by inductively coupled plasma atomic emission spectroscopy (ICP-AES) and inductively coupled plasma sector field mass spectrometry (ICP-SF-MS). RESULTS: The injected dose was rapidly excreted, with only 1.0% remaining in the body at 24 h. The radioactivity thereafter was mainly associated with kidney cortex, liver, lung, muscle and skin, with a similar rate of clearance for both ligand and Gd from these tissues. The ratio between (14)C-labelled substance and Gd was not significantly different from that of the injected substance in most tissue samples up to 24 h after injection; the ratio then slowly decreased. CONCLUSIONS: The data clearly show that measurements of Gd concentration alone in tissue samples from animals injected with Gd-based contrast agents (GBCAs) cannot be used as a measure of Gd released from the ligand. To our knowledge, such measurements comparing Gd and ligand concentrations and distribution in tissue samples have not been published previously for any of the commercial GBCAs.